ai3Bio

ai3Bio is a biotechnology company targeting autoimmune disease at its root source. From its funding announcement.

$48M Series ARaised yesterdayWatertown, USABiotech & PharmaUSA
Visit website →

In their own words

What ai3Bio says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "biotechnology company targeting autoimmune disease at its root source". Source

ProductResearch and development

Public signal Read from the company's own description of what the funding supports.

Why now

Where ai3Bio is today

ai3Bio announced a Series A round of $48M on 29 September 2026, led by founding investors UPMC Enterprises and Ziff Capital Partners.

Latest round
Series A
Amount
$48M
Announced
29 September 2026
Headquarters
Watertown, USA
Sector
Biotech & Pharma
Investors
Also participating
Cockrell Interests, Tanis Ventures
Relevant leadership
CEO Steven Altschuler

Momentum AfterRaise intelligence

AfterRaise Score

71
Building momentum
1 funding signal in the last 90 days
Funding recency
40/40
announced within the last 30 days
Round scale
16/25
round size relative to the market
Funding stage
15/20
Series A
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 29 September 2026
    $48M Series A
    Led by founding investors UPMC Enterprises and Ziff Capital Partners.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Product launches and new tiers
  • Product leadership hiring
  • Research programme expansion
  • Scientific team growth

Opportunities this could create

  • Clinical operations
  • Scientific hiring
  • Licensing and BD partnerships
  • Product leadership
  • Design partners

Based on the Biotech & Pharma sector, a Series A round and the priorities the company itself set out. Not a statement of fact.

Medium momentum3 connected signals
  • 29 September 2026$48M Series A announced
  • 29 September 2026Stated priority: product
  • 29 September 2026Stated priority: research and development

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What ai3Bio is open to

Not yet specified

ai3Bio has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with ai3Bio

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at ai3Bio?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: the roles and projects you have open. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector